Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with ...
Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...
2.35 PHP 0.02 0.86% ...
Featured here, the Balance Sheet for AllDay Marts Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 period ending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback